Recently, in vitro studies on iPSCs-derived MNs showed efficacy of several compounds (some of them already used to treat ALS or epilepsy) in rescuing both mitochondrial dysfunctions and SMA phenotypes—with or without increasing SMN protein levels—adding new promising candidates for a therapy [74,76,85,109]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.